OBJECTIVE：To study the pharmacokinetic characteristics of triflusal capsule in healthy volunteers. METHODS：In randomized test，36 healthy volunteers were randomly divided into 3 groups. They were given low-dose，medium-dose and high-dose of Triflusal capsule（300 mg，600 mg and 900 mg），qd，for one day，and then pharmacokinetic study of single dose of Triflusal capsule was conducted；Triflusal capsule medium-dose group was continuously given medicine for 13 days，and then pharmacokinetic study of multiple dose of Triflusal capsule was conducted. The plasma concentration of triflusal was determined by LC-MS/MS，and Zorbax SB-C18 column was used with methanol-0.2％ formic acid（80 ∶ 20，V/V）at the flow rate of 0.2 ml/min. ESI was adopted in MRM mode，negative ion detection was carried out，quantitative analysis m/z 247.1→161.1（triflusal），m/z 294.0→250.0（internal standard， diclofenac sodium）. Pharmacokinetic parameters were calculated by using WinNonlin 6.2 software，and the difference of them were compared. RESULTS：The linear range of triflusal were 0.05-20 μg/ml. The main pharmacokinetic parameters of triflusal capsules high-dose，medium-dose and low-dose groups were as follows：t1/2 were（0.45 ± 0.20），（0.47 ± 0.10），（0.43 ± 0.20）h；tmax were （0.56±0.20），（0.60±0.20），（0.47±0.40）h；cmax were（3.30±0.98），（10.65±3.26），（13.96±4.88）μg/ml；AUC0-8 h were（3.99±0.93）， （13.29±1.72），（19.62±6.78）μg·h/ml；within dose of 300-900 mg，linear relationship was found between cmax，AUC0-8 h and dose（R2＝ 0.954，0.986）. When reaching stable state of multiple dose，average blood concentration was（0.71±0.20）μg/ml；main pharmacokinetic parameters were as follows：AUCss（17.10±4.82）μg·h/ml，t1/2（0.49±0.10）h，tmax（0.85±0.62）h，cmax（11.58±3.99）μg/ml，AUC0-8 h （16.99±4.84）μg·h/ml，AUC0- ∞（17.08±4.81）μg·h/ml；accumulation factor（1.28±0.40）. tmax and t1/2 of single dose were similar to those of multiple dose. CONCLUSIONS：LC-MS/MS can determine the content of triflusal in human plasma rapidly and accurately， and accumulation phenomena exist in healthy Chinese volunteers，which shows linear pharmacokinetic characteristics.